Bridging Clinical Medicine and Advanced Analytics

Request Service | Why US | Service Portfolio |

Specialized data and safety CRO. We combine elite MD clinical oversight, advanced bioinformatics, and robust epidemiology to accelerate regulatory success for mid-sized biotechs and novel therapeutic innovators.

I-IV+

Trial Phases

30+

Yrs Expert

94k+

Community Impact

Helix

What We Do ~ Who We Serve

"Accelerate the delivery of next-generation therapeutics by uniting elite medical safety oversight with advanced bioinformatics, data science, and rigorous regulatory compliance"

1. Interventional Biostatistics & Bioinformatics

We transform complex clinical data and high-dimensional multi-omic sequencing datasets into regulatory-ready evidence. Operating in fully validated SAS/R environments, we specialize in the quantitative architecture of Phase I–III interventional trials.

Our Focus: Advanced Statistical Analysis Plans (SAPs), adaptive trial designs, sample size optimization, and fully CDISC-compliant statistical pipelines (SDTM/ADaM) that ensure your interventional data survives strict regulatory scrutiny.

2. Real-World Evidence (RWE) & Phase IV Surveillance

We bridge the gap between controlled clinical trials and real-world clinical practice. We design and execute rigorous observational studies, natural history registries, and prospective patient cohorts. By integrating Electronic Health Records (EHR), registry data, and claims databases, we generate robust Real-World Evidence to fulfill post-market regulatory commitments and maximize global market access.

3. Synthetic & External Control Arms

For advanced therapeutics where traditional control groups are logistically or ethically impossible, we build validated External and Synthetic Control Arms. By combining protocol epidemiology with advanced propensity score matching and historical clinical trial datasets, we drastically reduce live patient recruitment burdens and accelerate timelines for rare disease and oncology innovators.

4. Medical Monitoring & Pharmacovigilance

We safeguard both your live interventional trials and post-market observational programs with end-to-end adverse event (AE) tracking, real-time signal detection, and global safety reporting. Led directly by our founding physician and epidemiologist, we offer high-touch, rigorous medical oversight that guarantees absolute compliance with FDA and EMA safety standards.

Biotechnology & Pharma Innovators

We serve early-to-mid-stage drug developers (with a specialized focus on Oncology and Rare Diseases) who require agile, high-touch clinical data management, complex biostatistical modeling, and safety oversight without the rigid overhead and slow timelines.

Cell & Gene Therapy Pioneers

Advanced modalities generate unique data friction. We partner with cell and gene therapy innovators to process, clean, and analyze high-dimensional multi-omic datasets, managing the dual burden of complex biological data structures and stringent longitudinal safety monitoring.

Ecosystem & Legacy CRO Partners

We act as a specialized, white-labeled data and safety acceleration engine for traditional CROs. By deploying our asset-light digital infrastructure, we help legacy partners scale up their complex biostatistics, advanced epidemiology, and global pharmacovigilance (PV) operations on demand.

Capabilities

From multi-omic analytics to medical-led pharmacovigilance, our asset-light infrastructure delivers the regulatory-grade data integrity.

+ Let's Talk

Phase 1-IV &
Real-World Evidence (RWE)

Bioinformatics & Biostatistics

Pharmacovigilance (PV) & End-to-End Safety

Decentralized Trial (DCT) Data Management

Our
Primary

Service

Portfolio

Specialized

Modern clinical development cannot afford communication gaps between data scientists and medical clinicians. We built Inshirah Ventures to unify them.

Chief Medical & Safety Officer (MD,PhD,MPH)

A Physician-Scientiat with clinical medicine, epidemiology, and global pharmacovigilance expertise.

Chief Executive & Data Officer (PhD,MPH)

A computational scientist specializing in Bioinformatics, Epidemiology, and Biostatistics.

Our
Elite

Leadership

Inshirah Advantage

We bridge the gap between clinical medicine and computational data science. Operating on a digital-first, asset-light model, we bypass the heavy capital expenditure of physical trial sites to focus entirely on data integrity, advanced analytics, and clinical safety.

Direct Founder Oversight

Asset-Light Agility

Bridges Medicine & Data Science

Built for Novel Modalities

Why
Choose

0{{current_slide_index}}

/0{{total_slide_count}}

Epidemiology & Pharmacovigilance Team

Focuses on proactive safety science, regulatory compliance, and real-world therapeutic value.

Full Profile

Data, Bioinformatics & Biostatistics Team

Focuses on turning complex, high-dimensional datasets into clean, submission-ready clinical intelligence.

Full Profile

FAQs

What tools do you use?
For statistical modeling, data parsing, and epidemiological pipelines, we leverage robust programming environments including R (Bioconductor) and Python. For clinical trial management and safety monitoring databases, we deploy industry-standard, fully validated platforms (Veeva Vault and Oracle Argus) to meet client-specific study requirements.

How do you secured client data?
Data integrity and compliance are our absolute priorities. All projects are executed within architecture fully compliant with FDA 21 CFR Part 11, HIPAA, and GDPR regulations. We employ multi-factor authenticated, enterprise-grade encrypted storage environments, ensuring strict data segregation and comprehensive audit trails throughout the trial lifecycle.

Do you support genomic and multi-omics data integration?
Yes. Backed by our core expertise in bioinformatics, we go beyond standard data capture to process, integrate, and analyze high-throughput genomic and proteomic data. We build the specialized pipelines and statistical analysis plans required to transform complex datasets into actionable, regulatory-ready results.

How do you protect our asset's regulatory timeline and valuation?
We proactively mitigate risk by combining medical oversight with population-level epidemiology. Led by our founding MD, our end-to-end pharmacovigilance tracks safety trends in real time to catch adverse signals early, defend your asset, and build regulatory-grade Real-World Evidence that preserves market value.

Contact ~ General Inquiry

Please use this form for general inquiries and questions about our service requirements. Note: We do not accept RFPs, job inquiries, or business solicitations through this channel.

Based in the United States
Pennsylvania | Delaware | New Jersey | Maryland

Request a call - complete form

inquiry@inshirahconsult.com